Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 14/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 14/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963923 | 1.00 | HSD17B1 (0.65) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL20288135 | 0.80 | HPGD (0.48) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1180152 | 0.78 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL883778 | 0.77 | ALDH1A1 (0.44) | HSD17B1HSD17B2CNR1CYP2B6 | |
| SCHEMBL30469298 | 0.77 | RECQL (0.53) | HSD17B1HSD17B2CYP3A4CNR1 | |
| SCHEMBL30172682 | 0.77 | KDM4E (0.46) | HSD17B1HSD17B2CYP3A4CNR1ESR2 | |
| SCHEMBL20557565 | 0.77 | RECQL (0.53) | HSD17B1HSD17B2CYP3A4CNR1 | |
| SCHEMBL29290324 | 0.77 | KDM4E (0.46) | HSD17B1HSD17B2CYP3A4CNR1ESR2 | |
| SCHEMBL69369 | 0.76 | HSD17B1 (0.88) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4244577 | 0.76 | DAO (0.44) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | HSD17B1 2342/4885HSD17B2 2758/4885CYP3A4 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.